Interface Biologics Inc.
$48,333.00 CAD
≈ 7 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2021-2022
- Agreement period
- May 1, 2021 – February 28, 2022
- Reference
- nrc-cnrc:172-2021-2022-Q1-971223
Published purpose
Endexo anti-thrombogenic additives, (not coatings) are low molecular weight fluoro-oligomers that impart a passive surface to the implantable medical device thereby reducing platelet adhesion and thrombus formation. Interface Biologics will perform research and development on the Endexo surface modifying technology in support of its partner(s). Feasibility and development of novel formulations to be tested and used in specific medical device applications will be conducted over the course of the project.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions